Europe Cancer Therapeutics Market Size and Share

European Cancer Therapies Market Industry Summary
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Europe Cancer Therapeutics Market Analysis by Mordor Intelligence

The Europe oncology drugs market size stands at USD 61.46 billion in 2025 and is forecast to reach USD 79.87 billion by 2030, expanding at a 5.38% CAGR. This steady trajectory reflects regulatory harmonization by the European Medicines Agency (EMA), precision-medicine expansion under the EU Beating Cancer Plan, and sustained R&D investment in leading economies such as Germany and France. Intensifying competition centers on antibody-drug conjugates and radioligand therapies, while biosimilar uptake accelerates cost containment efforts across public health systems[1]Source: European Federation of Pharmaceutical Industries and Associations, “Cancer-care indicators,” efpia.eu. Cross-border CAR-T manufacturing, digital biomarker deployment, and a venture-capital surge in radiopharmaceutical start-ups further widen addressable demand. Cost pressures, divergent health-technology assessment (HTA) timelines, and nuclear-medicine infrastructure gaps remain the principal obstacles to timely patient access.  

Key Report Takeaways

  • Chemotherapy held a 42.35% Europe oncology drugs market share in 2024, while targeted therapy is projected to advance at a 6.23% CAGR through 2030.
  • Breast cancer accounted for 25.45% of the Europe oncology drugs market size in 2024; lung cancer is set to register a 6.89% CAGR to 2030.
  • PD-1/PD-L1 inhibitors commanded 31.84% share of the Europe oncology drugs market size in 2024, whereas antibody-drug conjugates are poised for 7.12% CAGR growth.
  • Intravenous formulations dominated with 68.82% share of the Europe oncology drugs market size in 2024; subcutaneous delivery is forecast to expand at 7.09% CAGR.
  • Germany captured 28.23% Europe oncology drugs market share in 2024, and France is projected to deliver the fastest 8.56% CAGR through 2030.

Segment Analysis

By Therapy Type: Targeted approaches realign treatment standards

Chemotherapy retained a 42.35% share of the Europe oncology drugs market size in 2024, reflecting its entrenched role in combination regimens. Yet targeted therapy is forecast to post a 6.23% CAGR, propelled by HER2-low breast-cancer approvals and next-generation EGFR inhibitors that extend progression-free intervals. A maturing immunotherapy backbone increasingly pairs with precision inhibitors, enabling deeper responses across tumor types and elevating biomarker testing rates.  

Increasing clinical-trial density underscores strategic emphasis on tumor-agnostic indications, with basket-study designs compressing development cycles. Biosimilar erosion in traditional cytotoxics accelerates revenue migration toward precision platforms, prompting legacy manufacturers to replenish pipelines via licensing or bolt-on acquisitions. The shift also reorients hospital formularies toward outpatient administration, reinforcing payer preference for cost-effective, biomarker-guided protocols.

Europe Cancer Therapeutics Market: Market Share by Therapy Type
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

Get Detailed Market Forecasts at the Most Granular Levels
Download PDF

By Cancer Type: Innovation pivots growth toward lung cancer

Breast cancer dominated the Europe oncology drugs market size with 25.45% share in 2024, backed by entrenched screening programs and established treatment algorithms. However, lung cancer is slated for the fastest 6.89% CAGR through 2030 as first-line immunotherapy combinations and exon-20 insertion inhibitors unlock previously refractory segments.  

Environmental policy tightening on smoking and air-quality metrics may gradually temper incidence, yet rapid molecular-diagnostic adoption broadens eligible patient pools for targeted regimens in the near term. Pharmaceutical companies thus prioritize portfolio depth across genomic subsets, balancing blockbuster volume in hormone-positive breast cancer with high-growth revenue in niche lung-cancer mutations.

By Drug Class: ADCs headline the innovation pipeline

PD-1/PD-L1 inhibitors captured 31.84% of 2024 revenue, cementing immune-checkpoint blockade as a multimodal backbone. Antibody-drug conjugates now top the growth league at 7.12% CAGR, reflecting linker-payload advances that widen therapeutic windows. Enhanced potency has spurred label expansion into earlier lines, while competitive differentiation revolves around site-specific conjugation and bystander-kill payloads.  

Meanwhile, tyrosine-kinase inhibitors transition toward fourth-generation agents that overcome solvent-front mutations, and CDK4/6 inhibitors migrate into adjuvant settings. Pipeline clustering amplifies deal-making for proprietary conjugation platforms, with out-licensing models offering capital-efficient entry for mid-cap firms eager to gain exposure to the fast-scaling ADC arena.

Europe Cancer Therapeutics Market: Market Share by Therapy
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

Get Detailed Market Forecasts at the Most Granular Levels
Download PDF

By Mode of Administration: Subcutaneous formats reshape service delivery

Intravenous infusion maintained 68.82% share in 2024, yet subcutaneous formulations are projected to expand at a 7.09% CAGR through 2030 as health systems champion home-based care. On-body injectors for monoclonal antibodies reduce chair time and free oncology-day-unit capacity, dovetailing with workforce-optimization targets.  

Oral oncology pipelines also flourish, supported by adherence-monitoring apps and digital pill dispensers that mitigate compliance risks. Manufacturers investing in formulation science and device partnerships gain first-mover advantage, while payer scrutiny intensifies on intravenous price premiums absent clear clinical benefit over patient-centric routes.

Geography Analysis

Germany generated 28.23% of Europe oncology drugs market revenue in 2024, underpinned by EUR 7.4 billion annual pharmaceutical R&D outlays and dense Phase III trial networks in oncology centers of excellence. Early-benefit assessments facilitate rapid reimbursement for breakthrough therapies, encouraging manufacturers to prioritize German launches.  

France, projected to log an 8.56% CAGR to 2030, accelerates through national genomic-screening rollouts and expedited HTA pathways that cut average review times by 15% since 2023. Coupled with centralized hospital purchasing, the reforms streamline market entry for targeted agents, enlarging addressable patient pools in both urban and regional cancer institutes.  

The United Kingdom maintains sizable demand despite post-Brexit realignment, as the Medicines and Healthcare products Regulatory Agency (MHRA) mutual-recognition initiative preserves access to EMA dossiers. Italy and Spain advance via biosimilar uptake and oncology spending allocation increases, while Nordic countries leverage digital registries to optimize precision-medicine deployment. Central and Eastern European markets, though smaller, record double-digit nominal growth supported by EU Cohesion Fund investments in radiotherapy infrastructure.

Growth Rate by Region
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Get Analysis on Important Geographic Markets
Download PDF

Competitive Landscape

Europe’s oncology arena exhibits moderate concentration, with top five companies accounting for an estimated half of combined revenue in 2024. Roche, Novartis, and AstraZeneca defend leadership through life-cycle management and broad tumor-type coverage, exemplified by Roche’s three immunotherapy combinations achieving survival gains above 20% in pivotal studies.  

Strategic M&A intensified in 2024 with Novartis acquiring MorphoSys for EUR 2.7 billion and Merck KGaA buying SpringWorks for USD 3.9 billion to secure next-generation targeted assets. Antitrust vigilance remains high; the European Commission levied EUR 780 million in fines on anti-competitive conduct between 2018-2022[2]Source: European Commission, “Competition Enforcement in Pharmaceuticals 2018-2022,” ec.europa.eu . Joint ventures between big pharma and AI specialists, such as AstraZeneca’s USD 200 million oncology-AI pact, accelerate molecule-discovery velocity and refine trial-design efficiencies.  

Mid-cap firms bridge innovation gaps through risk-sharing collaborations; Genmab’s antibody-engineering expertise and Regeneron’s bispecific-platform alignment exemplify symbiotic models that de-risk capital-intensive indications. Radiopharmaceutical newcomers attract escalating valuations as isotope supply chains stabilize, while biosimilar pure-plays such as Sandoz parlay manufacturing scale into competitive price bids that constrain originator margins.

Europe Cancer Therapeutics Industry Leaders

  1. Amgen Inc.

  2. AstraZeneca PLC

  3. Bayer AG

  4. Bristol-Meyrs Squibb Company

  5. F. Hoffmann-La Roche Ltd

  6. *Disclaimer: Major Players sorted in no particular order
European Cancer Therapies Market Industry Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • July 2025: Bayer secured EU approval for darolutamide plus androgen-deprivation therapy in metastatic hormone-sensitive prostate cancer
  • May 2025: EMA’s CHMP backed inavolisib for PIK3CA-mutated ER-positive breast cancer after a 57% progression-risk reduction

Table of Contents for Europe Cancer Therapeutics Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Precision-oncology drug approvals surge post-EMA reforms
    • 4.2.2 Biosimilar oncology uptake lowering therapy costs
    • 4.2.3 Genomic screening roll-outs in EU27 national cancer plans
    • 4.2.4 Cross-border CAR-T manufacturing hubs in BeneluxA initiative
    • 4.2.5 VC funding boom for radioligand start-ups
    • 4.2.6 AI-driven trial-matching platforms shorten recruitment time
  • 4.3 Market Restraints
    • 4.3.1 Divergent HTA reimbursement timelines across EU-5
    • 4.3.2 Hospital capacity gap for nuclear-medicine–based therapies
    • 4.3.3 Oncology workforce shortages in CEE nations
    • 4.3.4 Rising supply-chain risk for critical API imports
  • 4.4 Value / Supply-Chain Analysis
  • 4.5 Regulatory Landscape
  • 4.6 Technological Outlook
  • 4.7 Porter’s Five Forces
    • 4.7.1 Threat of New Entrants
    • 4.7.2 Bargaining Power of Buyers
    • 4.7.3 Bargaining Power of Suppliers
    • 4.7.4 Threat of Substitutes
    • 4.7.5 Competitive Rivalry

5. Market Size & Growth Forecasts

  • 5.1 By Therapy Type (Value)
    • 5.1.1 Chemotherapy
    • 5.1.2 Targeted Therapy
    • 5.1.3 Immunotherapy
    • 5.1.4 Hormonal Therapy
    • 5.1.5 Others
  • 5.2 By Cancer Type (Value)
    • 5.2.1 Breast Cancer
    • 5.2.2 Lung Cancer
    • 5.2.3 Colorectal Cancer
    • 5.2.4 Prostate Cancer
    • 5.2.5 Hematologic Cancers
    • 5.2.6 Other Cancers
  • 5.3 By Drug Class (Value)
    • 5.3.1 PD-1/PD-L1 Inhibitors
    • 5.3.2 Tyrosine Kinase Inhibitors
    • 5.3.3 CDK4/6 Inhibitors
    • 5.3.4 Hormone Antagonists
    • 5.3.5 Antibody-Drug Conjugates
    • 5.3.6 Others
  • 5.4 By Mode of Administration (Value)
    • 5.4.1 Intravenous
    • 5.4.2 Subcutaneous
    • 5.4.3 Oral
    • 5.4.4 Other Routes
    • 5.4.5 Asia-Pacific
  • 5.5 Europe
    • 5.5.1 Germany
    • 5.5.2 United Kingdom
    • 5.5.3 France
    • 5.5.4 Italy
    • 5.5.5 Spain
    • 5.5.6 Rest of Europe

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
    • 6.3.1 F. Hoffmann-La Roche AG
    • 6.3.2 Novartis AG
    • 6.3.3 AstraZeneca PLC
    • 6.3.4 Pfizer Inc.
    • 6.3.5 Bristol-Myers Squibb Company
    • 6.3.6 Merck & Co., Inc.
    • 6.3.7 Sanofi S.A.
    • 6.3.8 Johnson & Johnson ( Janssen Biotech )
    • 6.3.9 GlaxoSmithKline PLC
    • 6.3.10 Bayer AG
    • 6.3.11 Eli Lilly and Company
    • 6.3.12 Amgen Inc.
    • 6.3.13 AbbVie Inc.
    • 6.3.14 Boehringer Ingelheim Int’l GmbH
    • 6.3.15 Ipsen S.A.
    • 6.3.16 Daiichi Sankyo Company Ltd.
    • 6.3.17 Takeda Pharmaceutical Company Ltd.
    • 6.3.18 Servier SAS
    • 6.3.19 Hikma Pharmaceuticals PLC

7. Market Opportunities & Future Outlook

  • 7.1 White-space & Unmet-Need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Europe Cancer Therapeutics Market Report Scope

As per the scope of the report, Europe cancer therapeutics are drugs that block the growth and proliferation of cancer, by interfering with specific molecules, such as DNA or proteins, which are involved in the growth or expansion of cancerous cells. The cancer therapeutics market is segmented by Treatment Type (Chemotherapy, Target Therapy, Immunotherapy (Biologic Therapy), Hormonal Therapy, Other Treatment Types), Cancer Type (Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Respiratory/Lung Cancer, Other Cancer Types), By End-Users (Hospitals, Specialty Clinics, Cancer and Radiation Therapy Centers, and Geography (Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe)). The report offers the value (in USD million) for the above segments.

By Therapy Type (Value)
Chemotherapy
Targeted Therapy
Immunotherapy
Hormonal Therapy
Others
By Cancer Type (Value)
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Hematologic Cancers
Other Cancers
By Drug Class (Value)
PD-1/PD-L1 Inhibitors
Tyrosine Kinase Inhibitors
CDK4/6 Inhibitors
Hormone Antagonists
Antibody-Drug Conjugates
Others
By Mode of Administration (Value)
Intravenous
Subcutaneous
Oral
Other Routes
Asia-Pacific
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
By Therapy Type (Value) Chemotherapy
Targeted Therapy
Immunotherapy
Hormonal Therapy
Others
By Cancer Type (Value) Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Hematologic Cancers
Other Cancers
By Drug Class (Value) PD-1/PD-L1 Inhibitors
Tyrosine Kinase Inhibitors
CDK4/6 Inhibitors
Hormone Antagonists
Antibody-Drug Conjugates
Others
By Mode of Administration (Value) Intravenous
Subcutaneous
Oral
Other Routes
Asia-Pacific
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

Which countries generate the largest and fastest growth in European oncology sales?

Germany contributed 28.23% of 2024 revenue, while France is forecast for the quickest 8.56% CAGR to 2030.

What therapy classes are expanding quickest in European cancer care?

Antibody-drug conjugates are projected to post the highest 7.12% CAGR through 2030 and are reshaping targeted-delivery strategies.

How will EMA reforms influence drug-launch timelines?

Conditional approvals and joint clinical assessments are cutting filing-to-launch intervals, allowing biomarker-driven agents to reach patients within one year of pivotal data.

Why is subcutaneous delivery gaining ground?

Patient preference for home treatment and hospital cost-containment targets drive a 7.09% CAGR for subcutaneous oncology formats through 2030.

What obstacles most hinder new therapy uptake?

Divergent national HTA reviews and limited nuclear-medicine facilities slow radiopharmaceutical adoption despite regulatory clearance.

Which region is expected to record the fastest procedural growth during the forecast period?

Asia-Pacific is poised for the highest growth as co

Page last updated on:

Europe Cancer Therapeutics Market Report Snapshots